534 related articles for article (PubMed ID: 29120911)
1. Immunotherapy for kidney cancer: status quo and the future.
Bedke J; Stühler V; Stenzl A; Brehmer B
Curr Opin Urol; 2018 Jan; 28(1):8-14. PubMed ID: 29120911
[TBL] [Abstract][Full Text] [Related]
2. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
Schmidinger M
Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in immunotherapy for kidney cancer.
Ball MW; Allaf ME; Drake CG
Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
[TBL] [Abstract][Full Text] [Related]
4. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M
Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737
[TBL] [Abstract][Full Text] [Related]
5. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
8. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
[No Abstract] [Full Text] [Related]
9. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
[TBL] [Abstract][Full Text] [Related]
10. T-cell checkpoint inhibitors in metastatic renal cell carcinoma.
Grünwald V
Curr Opin Urol; 2015 Sep; 25(5):411-5. PubMed ID: 26125506
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.
Ornstein MC; Wood LS; Hobbs BP; Allman KD; Martin A; Bevan M; Gilligan TD; Garcia JA; Rini BI
J Immunother Cancer; 2019 May; 7(1):127. PubMed ID: 31097024
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?
Anselmo Da Costa I; Rausch S; Kruck S; Todenhöfer T; Stenzl A; Bedke J
Expert Rev Anticancer Ther; 2017 Apr; 17(4):357-368. PubMed ID: 28162024
[TBL] [Abstract][Full Text] [Related]
13. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
Ahrens M; Scheich S; Hartmann A; Bergmann L;
Oncol Res Treat; 2019; 42(3):128-135. PubMed ID: 30799404
[TBL] [Abstract][Full Text] [Related]
14. The current state of immune checkpoint inhibitors in the first-line treatment of renal cancer.
Rassy EE; Khoury Abboud RM; Ibrahim N; Assi T; Aoun F; Kattan J
Immunotherapy; 2018 Sep; 10(12):1047-1052. PubMed ID: 30185138
[TBL] [Abstract][Full Text] [Related]
15. BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
Epaillard N; Simonaggio A; Elaidi R; Azzouz F; Braychenko E; Thibault C; Sun CM; Moreira M; Oudard S; Vano YA
Bull Cancer; 2020 Jun; 107(5S):eS22-eS27. PubMed ID: 32620212
[TBL] [Abstract][Full Text] [Related]
16. [Immunotherapy of Renal Cell Carcinoma].
Poprach A; Lakomý R; Büchler T
Klin Onkol; 2017; 30(Supplementum3):55-61. PubMed ID: 29239194
[TBL] [Abstract][Full Text] [Related]
17. Updates to the Management of Kidney Cancer.
Jonasch E
J Natl Compr Canc Netw; 2018 May; 16(5S):639-641. PubMed ID: 29784745
[TBL] [Abstract][Full Text] [Related]
18. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
19. Role of immunotherapy in kidney cancer.
Nazzani S; Bazinet A; Karakiewicz PI
Curr Opin Support Palliat Care; 2018 Sep; 12(3):325-333. PubMed ID: 30048250
[TBL] [Abstract][Full Text] [Related]
20. Designing novel immunocombinations in metastatic renal cell carcinoma.
Santoni M; Massari F; Aurilio G; Mollica V; Cimadamore A; Lopez-Beltran A; Cheng L; Battelli N; Nolé F; Montironi R
Immunotherapy; 2020 Dec; 12(17):1257-1268. PubMed ID: 32998603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
